1
|
Matveev EY, Dontsova OS, Avdeeva VV, Kubasov AS, Zhdanov AP, Nikiforova SE, Goeva LV, Zhizhin KY, Malinina EA, Kuznetsov NT. Synthesis and Structures of Lead(II) Complexes with Substituted Derivatives of the Closo-Decaborate Anion with a Pendant N 3 Group. Molecules 2023; 28:8073. [PMID: 38138563 PMCID: PMC10746007 DOI: 10.3390/molecules28248073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 12/05/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023] Open
Abstract
In this work, we studied lead(II) and cobalt(II) complexation of derivatives [2-B10H9O(CH2)2O(CH2)2N3]2- and [2-B10H9O(CH2)5N3]2- of the closo-decaborate anion containing pendant azido groups in the presence of 1,10-phenanthroline and 2,2'-bipyridyl. Mononuclear [PbL2{An}] and binuclear [Pb2L4(NO3)2{An}] lead complexes (where {An} is the N3-substituted boron cluster) were isolated and studied by IR spectroscopy and elemental analysis. The mononuclear lead(II) complex [Pb(phen)2[B10H9O(CH2)2O(CH2)2N3] and the binuclear lead(II) complex [Pb2(phen)4(NO3)2[B10H9O(CH2)5)N3] were determined by single-crystal X-ray diffraction. In complex [Pb2(phen)4(NO3)2[B10H9O(CH2)5)N3], the boron cluster is coordinated by the metal atom only via the 3c2e MHB bonds. In complex [Pb(phen)2[B10H9O(CH2)2O(CH2)2N3], the coordination environment of the metal includes BH groups of the boron cluster and the oxygen atom of the exo-polyhedral substituent. When the reaction was performed in a CH3CN/water mixture, the binuclear lead(II) complex [(Pb(bipy)NO3)(Pb(bipy)2NO3)(B10H9O(CH2)2O(CH2)2N3)]·CH3CN·H2O was isolated, where the boron cluster acts as a bridging ligand between lead atoms coordinated by the boron cage via the O atoms of the substituent and/or the BH groups. In the course of cobalt(II) complexation, the starting compound (Ph4P)2[B10H9O(CH2)5N3] was isolated and its structure was also determined by X-ray diffraction. Although a number of lead(II) complexes with coordinated N3 are known from the literature, no complexes with the boron cluster coordinated by the pendant N3 group involved in the metal coordination have been isolated.
Collapse
Affiliation(s)
- Evgenii Yu. Matveev
- Institute of Fine Chemical Technologies Named after M. V. Lomonosov, MIREA—Russian Technological University, Vernadskogo pr. 86, Moscow 119571, Russia; (E.Y.M.); (O.S.D.); (K.Y.Z.)
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| | - Olga S. Dontsova
- Institute of Fine Chemical Technologies Named after M. V. Lomonosov, MIREA—Russian Technological University, Vernadskogo pr. 86, Moscow 119571, Russia; (E.Y.M.); (O.S.D.); (K.Y.Z.)
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| | - Varvara V. Avdeeva
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| | - Alexey S. Kubasov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| | - Andrey P. Zhdanov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| | - Svetlana E. Nikiforova
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| | - Lyudmila V. Goeva
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| | - Konstantin Yu. Zhizhin
- Institute of Fine Chemical Technologies Named after M. V. Lomonosov, MIREA—Russian Technological University, Vernadskogo pr. 86, Moscow 119571, Russia; (E.Y.M.); (O.S.D.); (K.Y.Z.)
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| | - Elena A. Malinina
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| | - Nikolay T. Kuznetsov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii pr. 31, Moscow 119991, Russia; (A.S.K.); (A.P.Z.); (S.E.N.); (L.V.G.); (E.A.M.); (N.T.K.)
| |
Collapse
|
2
|
Okada S, Nishimura K, Ainaya Q, Shiraishi K, Anufriev SA, Sivaev IB, Sakurai Y, Suzuki M, Yokoyama M, Nakamura H. Development of a Gadolinium-Boron-Conjugated Albumin for MRI-Guided Neutron Capture Therapy. Mol Pharm 2023; 20:6311-6318. [PMID: 37909734 DOI: 10.1021/acs.molpharmaceut.3c00726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2023]
Abstract
Noninvasive monitoring of boron agent biodistribution is required in advance of neutron capture therapy. In this study, we developed a gadolinium-boron-conjugated albumin (Gd-MID-BSA) for MRI-guided neutron capture therapy. Gd-MID-BSA was prepared by labeling bovine serum albumin with a maleimide-functionalized gadolinium complex and a maleimide-functionalized closo-dodecaborate orthogonally. The accumulation of Gd-MID-BSA in tumors in CT26 tumor-bearing mice reached a maximum at 24 h after the injection, as confirmed by T1-based MRI and biodistribution analysis using inductively coupled plasma optical emission spectrometry. The concentrations of boron and gadolinium in the tumors exceeded the thresholds required for boron neutron capture therapy (BNCT) and gadolinium neutron capture therapy (GdNCT), respectively. The boron concentration ratios of tumor to blood and tumor to normal tissues satisfied the clinical criteria, indicating the reduction of undesired nuclear reactions of endogenous nuclei. The molar ratio of boron to gadolinium in the tumor was close to that of Gd-MID-BSA, demonstrating that the accumulation of Gd-MID-BSA in the tumor can be evaluated by MRI. Thermal neutron irradiation with Gd-MID-BSA resulted in significant suppression of tumor growth compared to the group injected with a boron-conjugated albumin without gadolinium (MID-BSA). The neutron irradiation with Gd-MID-BSA did not cause apparent side effects. These results demonstrate that the conjugation of gadolinium and boron within the albumin molecule offers a novel strategy for enhancing the therapeutic effect of BNCT and the potential of MRI-guided neutron capture therapy as a promising treatment for malignant tumors.
Collapse
Affiliation(s)
- Satoshi Okada
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
| | - Kai Nishimura
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
| | - Qarri Ainaya
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
| | - Kouichi Shiraishi
- Division of Medical Engineering, Research Center for Medical Sciences, The Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan
| | - Sergey A Anufriev
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119334 Moscow, Russia
| | - Igor B Sivaev
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119334 Moscow, Russia
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori, Sennan, Osaka 590-0494, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori, Sennan, Osaka 590-0494, Japan
| | - Masayuki Yokoyama
- Division of Medical Engineering, Research Center for Medical Sciences, The Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
| |
Collapse
|
3
|
Nishimura K, Kashiwagi H, Morita T, Fukuo Y, Okada S, Miura K, Matsumoto Y, Sugawara Y, Enomoto T, Suzuki M, Nakai K, Kawabata S, Nakamura H. Efficient neutron capture therapy of glioblastoma with pteroyl-closo-dodecaborate-conjugated 4-(p-iodophenyl)butyric acid (PBC-IP). J Control Release 2023; 360:249-259. [PMID: 37356755 DOI: 10.1016/j.jconrel.2023.06.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 06/04/2023] [Accepted: 06/16/2023] [Indexed: 06/27/2023]
Abstract
Boron neutron capture therapy (BNCT) has been applied for clinical trials on glioblastoma patients since 1950s, however, the low survival rate under the treatments has hampered the widespread use of BNCT. In this study, we developed a novel boron agent, PBC-IP, which consists of three functional groups: FRα-targeting, 10B resource (twelve 10B atoms in the molecule), and albumin-binding moieties. PBC-IP was selectively taken up by glioma cell lines such as C6, F98, and U87MG cells and accumulated 10- to 20-fold higher than L-4‑boronophenylalanine (BPA). PBC-IP administrated intravenously to the human glioblastoma (U87MG) xenograft model showed higher boron accumulation in tumors (29.8 μg [10B]/g at 6 h) than BPA (9.6 μg [10B]/g at 3 h) at a 25 mg [10B]/kg dose, effectively suppressing tumor growth after thermal neutron irradiation. PBC-IP administrated via convection-enhanced delivery (CED) accumulated in the F98 glioma orthotopic rat model, achieving 26.5 μg [10B]/g in tumors with tumor/normal (T/N) brain and tumor/blood (T/B) boron ratios of 37.8 and 94.6, respectively, 3 h after CED. Survival at 180 days after BNCT was 50% in the PBC-IP group and 70% in the combined BPA and PBC-IP groups, with no residual brain tumors.
Collapse
Affiliation(s)
- Kai Nishimura
- School of Life Science and Technology, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan
| | - Hideki Kashiwagi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan
| | - Taiki Morita
- School of Life Science and Technology, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan; Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Yusuke Fukuo
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan
| | - Satoshi Okada
- School of Life Science and Technology, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan; Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Kazuki Miura
- School of Life Science and Technology, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan; Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Yoshitaka Matsumoto
- Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki 305-8575, Japan
| | - Yu Sugawara
- Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki 305-8575, Japan
| | - Takayuki Enomoto
- Biomaterials Analysis Division, Open Facility Center, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Kei Nakai
- Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki 305-8575, Japan
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan.
| | - Hiroyuki Nakamura
- School of Life Science and Technology, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan; Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259, Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan.
| |
Collapse
|
4
|
Monti Hughes A, Goldfinger JA, Palmieri MA, Ramos P, Santa Cruz IS, De Leo L, Garabalino MA, Thorp SI, Curotto P, Pozzi ECC, Kawai K, Sato S, Itoiz ME, Trivillin VA, Guidobono JS, Nakamura H, Schwint AE. Boron Neutron Capture Therapy (BNCT) Mediated by Maleimide-Functionalized Closo-Dodecaborate Albumin Conjugates (MID:BSA) for Oral Cancer: Biodistribution Studies and In Vivo BNCT in the Hamster Cheek Pouch Oral Cancer Model. LIFE (BASEL, SWITZERLAND) 2022; 12:life12071082. [PMID: 35888170 PMCID: PMC9323568 DOI: 10.3390/life12071082] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 07/11/2022] [Accepted: 07/14/2022] [Indexed: 12/12/2022]
Abstract
Background: BNCT (Boron Neutron Capture Therapy) is a tumor-selective particle radiotherapy that combines preferential boron accumulation in tumors and neutron irradiation. Although p-boronophenylalanine (BPA) has been clinically used, new boron compounds are needed for the advancement of BNCT. Based on previous studies in colon tumor-bearing mice, in this study, we evaluated MID:BSA (maleimide-functionalized closo-dodecaborate conjugated to bovine serum albumin) biodistribution and MID:BSA/BNCT therapeutic effect on tumors and associated radiotoxicity in the hamster cheek pouch oral cancer model. Methods: Biodistribution studies were performed at 30 mg B/kg and 15 mg B/kg (12 h and 19 h post-administration). MID:BSA/BNCT (15 mg B/kg, 19 h) was performed at three different absorbed doses to precancerous tissue. Results: MID:BSA 30 mg B/kg protocol induced high BSA toxicity. MID:BSA 15 mg B/kg injected at a slow rate was well-tolerated and reached therapeutically useful boron concentration values in the tumor and tumor/normal tissue ratios. The 19 h protocol exhibited significantly lower boron concentration values in blood. MID:BSA/BNCT exhibited a significant tumor response vs. the control group with no significant radiotoxicity. Conclusions: MID:BSA/BNCT would be therapeutically useful to treat oral cancer. BSA toxicity is a consideration when injecting a compound conjugated to BSA and depends on the animal model studied.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
- National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
- Correspondence: or ; Tel.: +54-9-11-41689832 or +54-11-6772-7927
| | - Jessica A. Goldfinger
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Mónica A. Palmieri
- Biodiversity and Experimental Biology Department, School of Exact and Natural Sciences, University of Buenos Aires, Av. Int. Güiraldes 2160, 4° piso, Pab. II, Ciudad Autónoma de Buenos Aires C1428EGA, Argentina;
| | - Paula Ramos
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Iara S. Santa Cruz
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Luciana De Leo
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Marcela A. Garabalino
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Silvia I. Thorp
- Department of Instrumentation and Control, National Atomic Energy Commission, Presbítero Juan González y Aragon, 15, Ezeiza, Buenos Aires B1802AYA, Argentina;
| | - Paula Curotto
- Department of Research and Production Reactors, National Atomic Energy Commission, Presbítero Juan González y Aragon, 15, Ezeiza, Buenos Aires B1802AYA, Argentina; (P.C.); (E.C.C.P.)
| | - Emiliano C. C. Pozzi
- Department of Research and Production Reactors, National Atomic Energy Commission, Presbítero Juan González y Aragon, 15, Ezeiza, Buenos Aires B1802AYA, Argentina; (P.C.); (E.C.C.P.)
| | - Kazuki Kawai
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.K.); (S.S.); (H.N.)
| | - Shinichi Sato
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.K.); (S.S.); (H.N.)
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan
| | - María E. Itoiz
- Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, M.T. de Alvear 2142, Ciudad Autónoma de Buenos Aires C1122AAH, Argentina;
| | - Verónica A. Trivillin
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
- National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Juan S. Guidobono
- Buenos Aires Institute of Ecology, Genetics and Evolution (IEGEBA), CONICET, UBA, Intendente Güiraldes 2160, Ciudad Universitaria, Ciudad Autónoma de Buenos Aires C1428EGA, Argentina;
| | - Hiroyuki Nakamura
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.K.); (S.S.); (H.N.)
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan
| | - Amanda E. Schwint
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
- National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| |
Collapse
|
5
|
Popova T, Dymova MA, Koroleva LS, Zakharova OD, Lisitskiy VA, Raskolupova VI, Sycheva T, Taskaev S, Silnikov VN, Godovikova TS. Homocystamide Conjugates of Human Serum Albumin as a Platform to Prepare Bimodal Multidrug Delivery Systems for Boron Neutron Capture Therapy. Molecules 2021; 26:molecules26216537. [PMID: 34770947 PMCID: PMC8586956 DOI: 10.3390/molecules26216537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 10/21/2021] [Accepted: 10/27/2021] [Indexed: 11/16/2022] Open
Abstract
Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)-a carrier protein with a long plasma half-life-is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-'click' chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro-closo-dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro-closo-dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.
Collapse
Affiliation(s)
- Tatyana Popova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Maya A Dymova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Ludmila S Koroleva
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Olga D Zakharova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Vladimir A Lisitskiy
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Valeria I Raskolupova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Tatiana Sycheva
- Budker Institute of Nuclear Physics, SB RAS, 630090 Novosibirsk, Russia
| | - Sergei Taskaev
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
- Budker Institute of Nuclear Physics, SB RAS, 630090 Novosibirsk, Russia
| | - Vladimir N Silnikov
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Tatyana S Godovikova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| |
Collapse
|
6
|
Abstract
"There's plenty of room at the bottom" (Richard Feynman, 1959): an invitation for (metalla)carboranes to enter the (new) field of nanomedicine. For two decades, the number of publications on boron cluster compounds designed for potential applications in medicine has been constantly increasing. Hundreds of compounds have been screened in vitro or in vivo for a variety of biological activities (chemotherapeutics, radiotherapeutics, antiviral, etc.), and some have shown rather promising potential for further development. However, until now, no boron cluster compounds have made it to the clinic, and even clinical trials have been very sparse. This review introduces a new perspective in the field of medicinal boron chemistry, namely that boron-based drugs should be regarded as nanomedicine platforms, due to their peculiar self-assembly behaviour in aqueous solutions, and treated as such. Examples for boron-based 12- and 11-vertex clusters and appropriate comparative studies from medicinal (in)organic chemistry and nanomedicine, highlighting similarities, differences and gaps in physicochemical and biological characterisation methods, are provided to encourage medicinal boron chemists to fill in the gaps between chemistry laboratory and real applications in living systems by employing bioanalytical and biophysical methods for characterising and controlling the aggregation behaviour of the clusters in solution.
Collapse
Affiliation(s)
- Marta Gozzi
- Institute of Inorganic ChemistryFaculty of Chemistry and MineralogyLeipzig UniversityJohannisallee 2904103LeipzigGermany
- Institute of Analytical ChemistryFaculty of Chemistry and MineralogyLeipzig UniversityLinnéstr. 304103LeipzigGermany
- Institute of Medicinal Physics and BiophysicsFaculty of MedicineLeipzig UniversityHärtelstr. 16–1804107LeipzigGermany
| | - Benedikt Schwarze
- Institute of Medicinal Physics and BiophysicsFaculty of MedicineLeipzig UniversityHärtelstr. 16–1804107LeipzigGermany
| | - Evamarie Hey‐Hawkins
- Institute of Inorganic ChemistryFaculty of Chemistry and MineralogyLeipzig UniversityJohannisallee 2904103LeipzigGermany
| |
Collapse
|
7
|
Gruzdev DA, Levit GL, Krasnov VP, Charushin VN. Carborane-containing amino acids and peptides: Synthesis, properties and applications. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2020.213753] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
8
|
Cyclic RGD-Functionalized closo-Dodecaborate Albumin Conjugates as Integrin Targeting Boron Carriers for Neutron Capture Therapy. Mol Pharm 2020; 17:3740-3747. [PMID: 32845640 DOI: 10.1021/acs.molpharmaceut.0c00478] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Cyclic RGD (cRGD) peptide-conjugated boronated albumin was developed to direct toward integrin αvβ3, which overexpresses on many cancer cells. A stepwise conjugation of c[RGDfK(Mal)] and maleimide-conjugated closo-dodecaborate (MID) to bovine serum albumin (BSA) afforded cRGD-MID-BSA, which was noncytotoxic toward both U87MG and A549 cells. As compared with l-BPA, selective antitumor activity of cRGD-MID-BSA toward U87MG cells overexpressing integrin αvβ3 was identified after thermal neutron irradiation. In vivo fluorescence live imaging of Cy5-conjugated cRGD-MID-BSA and MID-BSA revealed that both cRGD-MID-BSA and MID-BSA similarly reached the maximum accumulation during 8-12 h after injection. The selective accumulation and retention of Cy5-cRGD-MID-BSA was more pronounced than Cy5-MID-BSA after 24 h. An in vivo boron neutron capture therapy (BNCT) study revealed that the cRGD peptide ligand combination enhanced accumulation of MID-BSA into tumor cells in U87MG xenograft models. The significant tumor growth suppression was observed in U87MG xenograft models at a dose of 7.5 mg [10B]/kg after neutron irradiation.
Collapse
|
9
|
Nakagawa F, Kawashima H, Morita T, Nakamura H. Water-Soluble closo-Docecaborate-Containing Pteroyl Derivatives Targeting Folate Receptor-Positive Tumors for Boron Neutron Capture Therapy. Cells 2020; 9:cells9071615. [PMID: 32635272 PMCID: PMC7407413 DOI: 10.3390/cells9071615] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Revised: 06/30/2020] [Accepted: 06/30/2020] [Indexed: 11/16/2022] Open
Abstract
Water-soluble pteroyl-closo-dodecaborate conjugates (PBCs 1-4), were developed as folate receptor (FRα) targeting boron carriers for boron neutron capture therapy (BNCT). PBCs 1-4 had adequately low cytotoxicity with IC50 values in the range of 1~3 mM toward selected human cancer cells, low enough to use as BNCT boron agents. PBCs 1-3 showed significant cell uptake by FRα positive cells, especially U87MG glioblastoma cells, although the accumulation of PBC 4 was low compared with PBCs 1-3 and L-4-boronophenylalanine (L-BPA). The cellular uptake of PBC 1 and PBC 3 by HeLa cells was arrested by increasing the concentration of folate in the medium, indicating that the major uptake mechanisms of PBC 1-3 are primarily through FRα receptor-mediated endocytosis.
Collapse
Affiliation(s)
- Fumiko Nakagawa
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan;
| | - Hidehisa Kawashima
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan; (H.K.); (T.M.)
| | - Taiki Morita
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan; (H.K.); (T.M.)
| | - Hiroyuki Nakamura
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan;
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan; (H.K.); (T.M.)
- Correspondence: ; Tel.: +81-45-924-5244
| |
Collapse
|
10
|
Popova TV, Krumkacheva OA, Burmakova AS, Spitsyna AS, Zakharova OD, Lisitskiy VA, Kirilyuk IA, Silnikov VN, Bowman MK, Bagryanskaya EG, Godovikova TS. Protein modification by thiolactone homocysteine chemistry: a multifunctionalized human serum albumin theranostic. RSC Med Chem 2020; 11:1314-1325. [PMID: 34085043 PMCID: PMC8126878 DOI: 10.1039/c9md00516a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Accepted: 03/23/2020] [Indexed: 01/15/2023] Open
Abstract
As the most abundant protein with a variety of physiological functions, albumin has been used extensively for the delivery of therapeutic molecules. Thiolactone chemistry provides a powerful tool to prepare spin-labeled albumin-based multimodal imaging probes and therapeutic agents. We report the synthesis of a tamoxifen homocysteine thiolactone derivative and its use in thiol-'click' chemistry to prepare multi-functionalized serum albumin. The released sulfhydryl group of the homocysteine functional handle was labeled with a nitroxide reagent to prepare a spin-labeled albumin-tamoxifen conjugate confirmed by MALDI-TOF-MS, EPR spectroscopy, UV-vis and fluorescent emission spectra. This is the basis for a novel multimodal tamoxifen-albumin theranostic with a significant (dose-dependent) inhibitory effect on the proliferation of malignant cells. The response of human glioblastoma multiforme T98G cells and breast cancer MCF-7 cells to tamoxifen and its albumin conjugates was different in tumor cells with different expression level of ERα in our experiments. These results provide further impetus to develop a serum protein for delivery of tamoxifen to cancer cells.
Collapse
Affiliation(s)
- Tatyana V Popova
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
- Novosibirsk State University 630090 Novosibirsk Russia
| | - Olesya A Krumkacheva
- Novosibirsk State University 630090 Novosibirsk Russia
- International Tomography Center SB RAS 630090 Novosibirsk Russia
| | - Anna S Burmakova
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
- Novosibirsk State University 630090 Novosibirsk Russia
| | - Anna S Spitsyna
- Novosibirsk State University 630090 Novosibirsk Russia
- Novosibirsk Institute of Organic Chemistry SB RAS 630090 Novosibirsk Russia
| | - Olga D Zakharova
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
| | - Vladimir A Lisitskiy
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
| | - Igor A Kirilyuk
- Novosibirsk Institute of Organic Chemistry SB RAS 630090 Novosibirsk Russia
| | - Vladimir N Silnikov
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
| | - Michael K Bowman
- Novosibirsk Institute of Organic Chemistry SB RAS 630090 Novosibirsk Russia
- University of Alabama Tuscaloosa Alabama 35487-0336 USA
| | - Elena G Bagryanskaya
- Novosibirsk State University 630090 Novosibirsk Russia
- Novosibirsk Institute of Organic Chemistry SB RAS 630090 Novosibirsk Russia
| | - Tatyana S Godovikova
- Institute of Chemical Biology and Fundamental Medicine SB RAS 630090 Novosibirsk Russia
| |
Collapse
|
11
|
Kikuchi S, Sato S, Nakamura H. Carrier proteins-based boron delivery to tumor. Appl Radiat Isot 2019; 157:109011. [PMID: 31889673 DOI: 10.1016/j.apradiso.2019.109011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Revised: 11/03/2019] [Accepted: 11/29/2019] [Indexed: 10/25/2022]
Abstract
The conjugation of maleimide-functionalized closo-dodecaborate (MID) to transferrin (TF), which has no free SH cysteine residue, proceeded at room temperature for 12 h in PBS buffer (pH = 7.4). MID-TF conjugates were accumulated into the cells in the time- and concentration-dependent manners through the TF receptor mediated mechanism. In vivo biodistribution study of MID-TF conjugates in colon 26-bearing mice revealed the time-dependent selective accumulation of MID-TF conjugates into tumor very similar to that of MID-BSA. The tumor boron concentration of MID-BSA was higher than that of MID-TF conjugates (62 ppm vs. 20 ppm at a dose of 30 mg [B]/kg) 12 h after administration, suggesting that the EPR effect is not remarkably observed in the case of MID-TF conjugates because TF has smaller molecular weight than BSA (48 kDa vs. 68 kDa).
Collapse
Affiliation(s)
- Shunsuke Kikuchi
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Nagatsuta-cho, Midori-ku, Yokohama, 226-8503, Japan
| | - Shinichi Sato
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Nagatsuta-cho, Midori-ku, Yokohama, 226-8503, Japan
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Nagatsuta-cho, Midori-ku, Yokohama, 226-8503, Japan.
| |
Collapse
|